11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017; 389: 1195–1205.

Published: 26th April 2017

Authors: Cameron D, Piccart-Gebhart M, Gelber RD, Procter M, Goldhirsch A, de Azambuja E et al.

Conclusion

The study included 5099 women followed for a median of 11 years. One year of trastuzumab improved disease-free (hazard ratio 0.76, 95 per cent confidence interval 0.68 to 0.86) and overall survival (0.74, 0.64 to 0.86). There was no advantage in the second year of trastuzumab.

Pubmed Link

Your comments

0 Comments